tetano
Editor, Senior Moderator
Am J Gastroenterol
. 2021 Nov 9.
doi: 10.14309/ajg.0000000000001541. Online ahead of print.
Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study
Giovanni Marasco[SUP] 1 2 [/SUP], Cesare Cremon[SUP] 1 2 [/SUP], Maria Raffaella Barbaro[SUP] 1 [/SUP], Daniele Salvi[SUP] 2 [/SUP], Giulia Cacciari[SUP] 1 2 [/SUP], Anna Kagramanova[SUP] 3 [/SUP], Dmitry Bordin[SUP] 4 5 6 [/SUP], Vasile Drug[SUP] 7 [/SUP], Edgidia Miftode[SUP] 8 [/SUP], Pietro Fusaroli[SUP] 9 [/SUP], Salem Youssef Mohamed[SUP] 10 [/SUP], Chiara Ricci[SUP] 11 [/SUP], Massimo Bellini[SUP] 12 [/SUP], M Masudur Rahman[SUP] 13 [/SUP], Luigi Melcarne[SUP] 14 [/SUP], Javier Santos[SUP] 15 [/SUP], Beatriz Lobo[SUP] 15 [/SUP], Serhat Bor[SUP] 16 [/SUP], Suna Yapali[SUP] 17 [/SUP], Deniz Akyol[SUP] 18 [/SUP], Ferdane Pirincci Sapmaz[SUP] 19 [/SUP], Yonca Yilmaz Urun[SUP] 20 [/SUP], Tugce Eskazan[SUP] 21 [/SUP], Altay Celebi[SUP] 22 [/SUP], Huseyin Kacmaz[SUP] 23 [/SUP], Berat Ebik[SUP] 24 [/SUP], Hatice Cilem Binicier[SUP] 25 [/SUP], Mehmet Sait Bugdayci[SUP] 26 [/SUP], Munkhtsetseg Banzragch Yağcı[SUP] 27 [/SUP], Husnu Pullukcu[SUP] 18 [/SUP], Berrin Yalınbas Kaya[SUP] 20 [/SUP], Ali Tureyen[SUP] 20 [/SUP], İbrahim Hatemi[SUP] 21 [/SUP], Elif Sitre Koc[SUP] 17 [/SUP], Goktug Sirin[SUP] 22 [/SUP], Ali Riza Calıskan[SUP] 23 [/SUP], Goksel Bengi[SUP] 25 [/SUP], Esra Ergun Alıs[SUP] 28 [/SUP], Snezana Lukic[SUP] 29 [/SUP], Meri Trajkovska[SUP] 30 [/SUP], Keren Hod[SUP] 31 [/SUP], Dan Dumitrascu[SUP] 32 [/SUP], Antonello Pietrangelo[SUP] 33 [/SUP], Elena Corradini[SUP] 33 [/SUP], Magnus Simren[SUP] 34 [/SUP], Jessica Sjolund[SUP] 34 [/SUP], Navkiran Tornkvist[SUP] 34 [/SUP], Uday C Ghoshal[SUP] 35 [/SUP], Olga Kolokolnikova[SUP] 36 [/SUP], Antonio Colecchia[SUP] 37 [/SUP], Jordi Serra[SUP] 38 [/SUP], Giovanni Maconi[SUP] 39 [/SUP], Roberto De Giorgio[SUP] 40 [/SUP], Silvio Danese[SUP] 41 [/SUP], Pietro Portincasa[SUP] 42 [/SUP], Michele Di Stefano[SUP] 43 [/SUP], Marcello Maggio[SUP] 44 [/SUP], Elena Philippou[SUP] 45 [/SUP], Yeong Yeh Lee[SUP] 46 [/SUP], Alessandro Venturi[SUP] 1 [/SUP], Claudio Borghi[SUP] 1 2 [/SUP], Marco Zoli[SUP] 1 2 [/SUP], Paolo Gionchetti[SUP] 1 2 [/SUP], Pierluigi Viale[SUP] 1 2 [/SUP], Vincenzo Stanghellini[SUP] 1 2 [/SUP], Giovanni Barbara[SUP] 1 2 [/SUP], and the GI-COVID19 Study Group
Affiliations
Abstract
Introduction: Gastrointestinal (GI) symptoms in coronavirus-19 disease (COVID-19) have been reported with great variability and without standardization. In hospitalized patients, we aimed to evaluate the prevalence of GI symptoms, factors associated with their occurrence, and variation at 1 month.
Methods: The GI-COVID-19 is a prospective, multicenter, controlled study. Patients with and without COVID-19 diagnosis were recruited at hospital admission and asked for GI symptoms at admission and after 1 month, using the validated Gastrointestinal Symptom Rating Scale questionnaire.
Results: The study included 2036 hospitalized patients. A total of 871 patients (575 COVID+ and 296 COVID-) were included for the primary analysis. GI symptoms occurred more frequently in patients with COVID-19 (59.7%; 343/575 patients) than in the control group (43.2%; 128/296 patients) (P < 0.001). Patients with COVID-19 complained of higher presence or intensity of nausea, diarrhea, loose stools, and urgency as compared with controls. At a 1-month follow-up, a reduction in the presence or intensity of GI symptoms was found in COVID-19 patients with GI symptoms at hospital admission. Nausea remained increased over controls. Factors significantly associated with nausea persistence in COVID-19 were female sex, high body mass index, the presence of dyspnea, and increased C-reactive protein levels.
Discussion: The prevalence of GI symptoms in hospitalized patients with COVID-19 is higher than previously reported. Systemic and respiratory symptoms are often associated with GI complaints. Nausea may persist after the resolution of COVID-19 infection.
. 2021 Nov 9.
doi: 10.14309/ajg.0000000000001541. Online ahead of print.
Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study
Giovanni Marasco[SUP] 1 2 [/SUP], Cesare Cremon[SUP] 1 2 [/SUP], Maria Raffaella Barbaro[SUP] 1 [/SUP], Daniele Salvi[SUP] 2 [/SUP], Giulia Cacciari[SUP] 1 2 [/SUP], Anna Kagramanova[SUP] 3 [/SUP], Dmitry Bordin[SUP] 4 5 6 [/SUP], Vasile Drug[SUP] 7 [/SUP], Edgidia Miftode[SUP] 8 [/SUP], Pietro Fusaroli[SUP] 9 [/SUP], Salem Youssef Mohamed[SUP] 10 [/SUP], Chiara Ricci[SUP] 11 [/SUP], Massimo Bellini[SUP] 12 [/SUP], M Masudur Rahman[SUP] 13 [/SUP], Luigi Melcarne[SUP] 14 [/SUP], Javier Santos[SUP] 15 [/SUP], Beatriz Lobo[SUP] 15 [/SUP], Serhat Bor[SUP] 16 [/SUP], Suna Yapali[SUP] 17 [/SUP], Deniz Akyol[SUP] 18 [/SUP], Ferdane Pirincci Sapmaz[SUP] 19 [/SUP], Yonca Yilmaz Urun[SUP] 20 [/SUP], Tugce Eskazan[SUP] 21 [/SUP], Altay Celebi[SUP] 22 [/SUP], Huseyin Kacmaz[SUP] 23 [/SUP], Berat Ebik[SUP] 24 [/SUP], Hatice Cilem Binicier[SUP] 25 [/SUP], Mehmet Sait Bugdayci[SUP] 26 [/SUP], Munkhtsetseg Banzragch Yağcı[SUP] 27 [/SUP], Husnu Pullukcu[SUP] 18 [/SUP], Berrin Yalınbas Kaya[SUP] 20 [/SUP], Ali Tureyen[SUP] 20 [/SUP], İbrahim Hatemi[SUP] 21 [/SUP], Elif Sitre Koc[SUP] 17 [/SUP], Goktug Sirin[SUP] 22 [/SUP], Ali Riza Calıskan[SUP] 23 [/SUP], Goksel Bengi[SUP] 25 [/SUP], Esra Ergun Alıs[SUP] 28 [/SUP], Snezana Lukic[SUP] 29 [/SUP], Meri Trajkovska[SUP] 30 [/SUP], Keren Hod[SUP] 31 [/SUP], Dan Dumitrascu[SUP] 32 [/SUP], Antonello Pietrangelo[SUP] 33 [/SUP], Elena Corradini[SUP] 33 [/SUP], Magnus Simren[SUP] 34 [/SUP], Jessica Sjolund[SUP] 34 [/SUP], Navkiran Tornkvist[SUP] 34 [/SUP], Uday C Ghoshal[SUP] 35 [/SUP], Olga Kolokolnikova[SUP] 36 [/SUP], Antonio Colecchia[SUP] 37 [/SUP], Jordi Serra[SUP] 38 [/SUP], Giovanni Maconi[SUP] 39 [/SUP], Roberto De Giorgio[SUP] 40 [/SUP], Silvio Danese[SUP] 41 [/SUP], Pietro Portincasa[SUP] 42 [/SUP], Michele Di Stefano[SUP] 43 [/SUP], Marcello Maggio[SUP] 44 [/SUP], Elena Philippou[SUP] 45 [/SUP], Yeong Yeh Lee[SUP] 46 [/SUP], Alessandro Venturi[SUP] 1 [/SUP], Claudio Borghi[SUP] 1 2 [/SUP], Marco Zoli[SUP] 1 2 [/SUP], Paolo Gionchetti[SUP] 1 2 [/SUP], Pierluigi Viale[SUP] 1 2 [/SUP], Vincenzo Stanghellini[SUP] 1 2 [/SUP], Giovanni Barbara[SUP] 1 2 [/SUP], and the GI-COVID19 Study Group
Affiliations
- PMID: 34751672
- DOI: 10.14309/ajg.0000000000001541
Abstract
Introduction: Gastrointestinal (GI) symptoms in coronavirus-19 disease (COVID-19) have been reported with great variability and without standardization. In hospitalized patients, we aimed to evaluate the prevalence of GI symptoms, factors associated with their occurrence, and variation at 1 month.
Methods: The GI-COVID-19 is a prospective, multicenter, controlled study. Patients with and without COVID-19 diagnosis were recruited at hospital admission and asked for GI symptoms at admission and after 1 month, using the validated Gastrointestinal Symptom Rating Scale questionnaire.
Results: The study included 2036 hospitalized patients. A total of 871 patients (575 COVID+ and 296 COVID-) were included for the primary analysis. GI symptoms occurred more frequently in patients with COVID-19 (59.7%; 343/575 patients) than in the control group (43.2%; 128/296 patients) (P < 0.001). Patients with COVID-19 complained of higher presence or intensity of nausea, diarrhea, loose stools, and urgency as compared with controls. At a 1-month follow-up, a reduction in the presence or intensity of GI symptoms was found in COVID-19 patients with GI symptoms at hospital admission. Nausea remained increased over controls. Factors significantly associated with nausea persistence in COVID-19 were female sex, high body mass index, the presence of dyspnea, and increased C-reactive protein levels.
Discussion: The prevalence of GI symptoms in hospitalized patients with COVID-19 is higher than previously reported. Systemic and respiratory symptoms are often associated with GI complaints. Nausea may persist after the resolution of COVID-19 infection.